EAM
NVCR icon

Eagle Asset Management’s NovoCure NVCR Stock Holding History

Eagle Asset Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-279,158
Closed -$48.3M – 653
2020
Q4 		$48.3M Buy
+279,158
New +$38.2M 0.27% 135
2020
Q3 		– Sell
-31,711
Closed -$1.83M – 593
2020
Q2 		$1.83M Sell
31,711
-775,415
-96% -$51M 0.01% 454
2020
Q1 		$54.4M Sell
807,126
-6,578
-0.8% -$520K 0.34% 112
2019
Q4 		$68.6M Sell
813,704
-4,210
-0.5% -$340K 0.33% 113
2019
Q3 		$61.2M Buy
817,914
+665,321
+436% +$53.2M 0.32% 122
2019
Q2 		$9.65M Buy
+152,593
New +$7.73M 0.05% 316

Other funds holding NVCR

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Eagle Asset Management's NVCR Position: Q1 2021 in Review

Eagle Asset Management sold out of NovoCure (NVCR) in Q1 2021, closing a stake of 279,158 shares — an estimated $48.3M sold.

Eagle Asset Management first reported a position in NVCR in Q2 2019 and held it in 6 quarters. The position peaked at $68.6M in Q4 2019. 327 funds tracked by Wall St. Rank hold NVCR as of Q1 2021.

  • Eagle Asset Management reported no remaining NovoCure position as of Q1 2021 after selling out during the quarter.
  • Eagle Asset Management sold 279,158 NovoCure shares in Q1 2021, an estimated $48.3M.
  • Eagle Asset Management first reported a position in NovoCure in Q2 2019 and held it in 6 quarters.
  • Eagle Asset Management's NovoCure position peaked at $68.6M in Q4 2019.
  • 327 funds tracked by Wall St. Rank held NovoCure as of Q1 2021.

Based on Eagle Asset Management's 13F filing for Q1 2021, filed 14 May 2021.